Quibim
Whole-body medical imaging analysis
- 21-100 employees
- Healthcare
- B2B
- Artificial Intelligence
- Big data
- Deep Tech
- SaaS
- MedTech
- Mestalla, València, Spain
Jump to section
Company mission
to improve human health through AI-guided precision medicine.
Our take
Quibim develops quantitative biomarkers, companion diagnostics and other imaging tools for systems biology applications, from immuno-oncology to neurology. Specialising in advanced whole-body medical imaging, the company’s innovative AI-guided image analysis unlocks imaging data that enables doctors to make the best value-based care decisions for their patients.
The company’s algorithms find abnormalities and biomarkers in X-rays, CT scans, and PET scans to detect disease early. The company leads real-world evidence (RWE) projects with over 10 million de-identified research imaging registries from 50,000+ oncology patients.
Partnered with major phama companies and real-world data players, such as the Bradfield Centre, DE Healthcare, and Molecular Imaging Partners, the company is a leading reference imaging platform for some of the largest internal research consortiums and biobanks in cancer.
The company’s QP-Prostate software has received FDA 510(k) clearance, UKCA certification, and a CE mark, adding a major milestone to Quibim’s already impressive achievements.
Freddie
Company Specialist at Welcome to the Jungle
Funding (last 2 of 8 rounds)
Jan 2025
$50m
SERIES A
Nov 2021
$5.4m
SEED
Total funding: $66.8m
This company has top investors
Leadership
Dr. Ángel Alberich-Bayarri
(Co-Founder & CEO)Biomedical Imaging Research Group Collaborator at the Medical Research Institute La Fe and Board Menber at Startup Valencia.
Luis Martí Bonmatí
(Co-Founder)Director of the Medical Image Clinic at Hospital Universitario y Politécnico La Fe.